Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines
- PMID: 11884464
- DOI: 10.4049/jimmunol.168.6.2930
Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines
Abstract
The role of secretory IgA in conferring cross-protective immunity was examined in polymeric (p)IgR knockout (KO) mice immunized intranasally with different inactivated vaccines prepared from A/PR/8/34 (H1N1), A/Yamagata/120/86 (H1N1), A/Beijing/262/95 (H1N1), and B/Ibaraki/2/85 viruses and infected with the A/PR/8/34 virus in the upper respiratory tract (RT)-restricting volume. In wild-type mice, immunization with A/PR/8/34 or its variant (A/Yamagata/120/86 and A/Beijing/262/95) vaccines conferred complete protection or partial cross-protection against infection, while the B-type virus vaccine failed to provide protection. The protection or cross-protection was accompanied by an increase in the nasal A/PR/8/34 hemagglutinin-reactive IgA concentration, which was estimated to be >30 times the serum IgA concentration and much higher than the nasal IgG concentration. In contrast, the blockade of transepithelial transport of dimeric IgA in pIgR-KO mice reduced the degree of protection or cross-protection, in parallel with the marked increase in serum IgA concentration and the decrease in nasal IgA concentration (about 20 and 0.3 times those in wild-type mice, respectively). The degree of the reduction of protection or cross-protection was moderately reversed by the low but non-negligible level of nasal IgA, transudates from the accumulated serum IgA. These results, together with the absence of the IgA-dependent cross-protection in the lower RT and the unaltered level of nasal or serum IgG in wild-type and pIgR-KO mice, confirm that the actively secreted IgA plays an important role in cross-protection against variant virus infection in the upper RT, which cannot be substituted by serum IgG.
Similar articles
-
Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules.Eur J Immunol. 1991 Jun;21(6):1337-44. doi: 10.1002/eji.1830210602. Eur J Immunol. 1991. PMID: 1646112
-
Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase.Vaccine. 2002 Nov 22;21(1-2):60-6. doi: 10.1016/s0264-410x(02)00434-6. Vaccine. 2002. PMID: 12443663
-
Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit.Vaccine. 1988 Oct;6(5):409-13. doi: 10.1016/0264-410x(88)90140-5. Vaccine. 1988. PMID: 2848377
-
Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560. Jpn J Infect Dis. 2016. PMID: 27212584 Review.
-
Studies on the usefulness of intranasal inactivated influenza vaccines.Vaccine. 2010 Aug 31;28(38):6393-7. doi: 10.1016/j.vaccine.2010.05.019. Epub 2010 May 20. Vaccine. 2010. PMID: 20493820 Review.
Cited by
-
Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.Vaccine. 2012 Nov 6;30(48):6871-7. doi: 10.1016/j.vaccine.2012.09.007. Epub 2012 Sep 16. Vaccine. 2012. PMID: 22989689 Free PMC article.
-
Chimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 viruses.Sci Rep. 2017 Jan 9;7:40226. doi: 10.1038/srep40226. Sci Rep. 2017. PMID: 28067290 Free PMC article.
-
Immunological assessment of influenza vaccines and immune correlates of protection.Expert Rev Vaccines. 2013 May;12(5):519-36. doi: 10.1586/erv.13.35. Expert Rev Vaccines. 2013. PMID: 23659300 Free PMC article. Review.
-
Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA.Sci Immunol. 2021 Dec 10;6(66):eabj5129. doi: 10.1126/sciimmunol.abj5129. Epub 2021 Dec 10. Sci Immunol. 2021. PMID: 34890255 Free PMC article.
-
Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.Front Immunol. 2019 Mar 29;10:646. doi: 10.3389/fimmu.2019.00646. eCollection 2019. Front Immunol. 2019. PMID: 30984200 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous